BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36149549)

  • 21. Population Pharmacokinetics and Adverse Events of Erlotinib in Japanese Patients with Non-small-cell Lung Cancer: Impact of Genetic Polymorphisms in Metabolizing Enzymes and Transporters.
    Endo-Tsukude C; Sasaki JI; Saeki S; Iwamoto N; Inaba M; Ushijima S; Kishi H; Fujii S; Semba H; Kashiwabara K; Tsubata Y; Hayashi M; Kai Y; Saito H; Isobe T; Kohrogi H; Hamada A
    Biol Pharm Bull; 2018; 41(1):47-56. PubMed ID: 29311482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment?
    Magliulo L; Dahl ML; Lombardi G; Fallarini S; Villa LM; Biolcati A; Scordo MG
    Eur J Clin Pharmacol; 2011 Jan; 67(1):47-54. PubMed ID: 20931330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of ABCB1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of quetiapine in healthy volunteers.
    Kim KA; Joo HJ; Lee HM; Park JY
    Pharmacogenet Genomics; 2014 Jan; 24(1):35-42. PubMed ID: 24240480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of the CYP3A4/5 genetic score and ABCB1 polymorphisms on tacrolimus exposure and renal function in Brazilian kidney transplant patients.
    Genvigir FD; Salgado PC; Felipe CR; Luo EY; Alves C; Cerda A; Tedesco-Silva H; Medina-Pestana JO; Oliveira N; Rodrigues AC; Doi SQ; Hirata MH; Hirata RD
    Pharmacogenet Genomics; 2016 Oct; 26(10):462-72. PubMed ID: 27434656
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of pharmacokinetics-related genetic polymorphisms on the side effect profile of afatinib in patients with non-small cell lung cancer.
    Hayashi H; Iihara H; Hirose C; Fukuda Y; Kitahora M; Kaito D; Yanase K; Endo J; Ohno Y; Suzuki A; Sugiyama T
    Lung Cancer; 2019 Aug; 134():1-6. PubMed ID: 31319966
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of ABCB1 polymorphisms on the pharmacokinetics and toxicity of lenalidomide in patients with multiple myeloma.
    Kobayashi T; Miura M; Abumiya M; Akamine Y; Ito F; Takahashi N
    Med Oncol; 2019 May; 36(6):55. PubMed ID: 31089832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer: The OSIBOOST trial.
    van Veelen A; Gulikers J; Hendriks LEL; Dursun S; Ippel J; Smit EF; Dingemans AC; van Geel R; Croes S
    Lung Cancer; 2022 Sep; 171():97-102. PubMed ID: 35933915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor.
    Koo DH; Ryu MH; Ryoo BY; Beck MY; Na YS; Shin JG; Lee SS; Kim EY; Kang YK
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):173-82. PubMed ID: 25417047
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non-small-cell lung cancer.
    Akasaka K; Kaburagi T; Yasuda S; Ohmori K; Abe K; Sagara H; Ueda Y; Nagao K; Imura J; Imai Y
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):691-8. PubMed ID: 20035425
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.
    Rudin CM; Liu W; Desai A; Karrison T; Jiang X; Janisch L; Das S; Ramirez J; Poonkuzhali B; Schuetz E; Fackenthal DL; Chen P; Armstrong DK; Brahmer JR; Fleming GF; Vokes EE; Carducci MA; Ratain MJ
    J Clin Oncol; 2008 Mar; 26(7):1119-27. PubMed ID: 18309947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment.
    Fiegenbaum M; da Silveira FR; Van der Sand CR; Van der Sand LC; Ferreira ME; Pires RC; Hutz MH
    Clin Pharmacol Ther; 2005 Nov; 78(5):551-8. PubMed ID: 16321621
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of
    Yagishita H; Kagaya H; Saito M; Numakura K; Yamamoto R; Sagehashi R; Habuchi T; Satoh S; Miura M
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233042
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ABCB1, ABCG2 and CYP2D6 polymorphism effects on disposition and response to long-acting risperidone.
    Ganoci L; Trkulja V; Živković M; Božina T; Šagud M; Lovrić M; Božina N
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jan; 104():110042. PubMed ID: 32682874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of CYP3A5 genotype on tolvaptan pharmacokinetics and their relationships with endogenous markers of CYP3A activity and serum sodium level in heart failure patients.
    Hoshikawa K; Naito T; Akutsu S; Saotome M; Maekawa Y; Kawakami J
    Basic Clin Pharmacol Toxicol; 2020 Apr; 126(4):353-363. PubMed ID: 31652395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers.
    Belmonte C; Ochoa D; Román M; Saiz-Rodríguez M; Wojnicz A; Gómez-Sánchez CI; Martín-Vílchez S; Abad-Santos F
    Basic Clin Pharmacol Toxicol; 2018 Jun; 122(6):596-605. PubMed ID: 29325225
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.
    Cotte S; von Ahsen N; Kruse N; Huber B; Winkelmann A; Zettl UK; Starck M; König N; Tellez N; Dörr J; Paul F; Zipp F; Lühder F; Koepsell H; Pannek H; Montalban X; Gold R; Chan A
    Brain; 2009 Sep; 132(Pt 9):2517-30. PubMed ID: 19605531
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ABCB1 c.3435C>T polymorphism is associated with platinum toxicity: a preliminary study.
    De Troia B; Dalu D; Filipazzi V; Isabella L; Tosca N; Ferrario S; Gambaro AR; Somma L; Fasola C; Cheli S; Clementi E; De Francesco D; Falvella FS; Cattaneo MT
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):803-808. PubMed ID: 30796464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantification of the steady-state plasma concentrations of clozapine and N-desmethylclozapine in Japanese patients with schizophrenia using a novel HPLC method and the effects of CYPs and ABC transporters polymorphisms.
    Akamine Y; Sugawara-Kikuchi Y; Uno T; Shimizu T; Miura M
    Ann Clin Biochem; 2017 Nov; 54(6):677-685. PubMed ID: 27932669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.
    Jun KR; Lee W; Jang MS; Chun S; Song GW; Park KT; Lee SG; Han DJ; Kang C; Cho DY; Kim JQ; Min WK
    Transplantation; 2009 Apr; 87(8):1225-31. PubMed ID: 19384171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.